Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 07/02/2024 at 13:30, 1 year 6 months ago

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness

Moderna Inc. MRNA Technology BARDA Pandemic Influenza Vaccine Global Public Health
BRIEF

published on 06/28/2024 at 13:05, 1 year 7 months ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 1 year 7 months ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 1 year 7 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 1 year 7 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 1 year 7 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 1 year 7 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 1 year 7 months ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
PRESS RELEASE

published on 06/07/2024 at 16:30, 1 year 7 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 1 year 7 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Published on 01/31/2026 at 03:15, 1 day 14 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 1 day 15 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 1 day 16 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 1 day 18 hours ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 1 day 19 hours ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 1 day 2 hours ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 5 hours ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 15 hours ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 20 hours ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 21 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 17:45, 2 days ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 2 days 10 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 3 days ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 3 days ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 3 days ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News